We have an updated report [Version - 2023] available. Kindly sign up to get the sample of the report.
all report title image
  • Published On : Oct 2022
  • Code : CMI566
  • Industry : Medical Devices
  • Pages : 150
  • Formats :

Drug eluting stents are small expandable mesh tubes made up of medical-grade stainless steel or cobalt alloy metal that are inserted into the coronary arteries of patients suffering from atherosclerosis. The stent helps to hold the artery open to release a drug that prevents blockage in the artery and improves blood flow in the artery.

Stents are mainly used in procedures such as coronary angioplasty. Drug eluting stents are used in the treatment of coronary artery disease and coronary angioplasty such as percutaneous coronary interventions (PCI) and others. Drug eluting stents comprise three parts which include stent platform, polymer coating (which holds the drug into the stent), and the drug.

The global drug eluting stents market is estimated to be valued at US$ 2,897.2 million in 2022 and is expected to witness a CAGR of 6.6% during the forecast period (2022–2030).

Figure 1. Global Drug Eluting Stents Market Share (%), by Application, 2022

Drug Eluting Stents  | Coherent Market Insights

Global Drug Eluting Stents Market – Drivers

Increasing product approvals are expected to drive the global drug eluting stents market growth over the forecast period. Manufacturers of drug eluting stents are focused on gaining regulatory approval to market their products and fulfill the unmet medical needs in cardiac care. For instance, in December 2021, the U.S. Food and Drug Administration (FDA) approved SLENDER IDS fixed-wire and DIRECT RX rapid-exchange drug-eluting stent (DES) systems for the treatment of coronary artery disease by Svelte Medical, a healthcare company. Both the products, SLENDER IDS and DIRECT RX, are highly deliverable drug eluting stent systems which provide long-term clinical outcomes in the coronary artery patient population.

The increasing prevalence of cardiovascular diseases is expected to drive demand for its treatment and surgical intervention, which in turn is expected to fuel the global drug eluting stents market growth. For instance, according to the data published by the National Center for Biotechnology Information in July 2020, ischemic heart disease, also referred to as coronary artery disease (CAD) and atherosclerotic cardiovascular disease (ACD), is a leading cause of premature mortality.

CMI table icon

Drug Eluting Stents Market Report Coverage

Report Coverage Details
Base Year: 2021 Market Size in 2022: US$ 2,897.2 Mn
Historical Data for: 2017 to 2020 Forecast Period: 2022 to 2030
Forecast Period 2022 to 2030 CAGR: 6.6% 2030 Value Projection: US$ 4,844.6 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Drug: Sirolimus, Paclitaxel, Zotarolimus, Everolimus, Biolimus, Others
  • By Coating Type: Polymer-based Coatings, Polymer-free Coatings
  • By Application: Coronary Artery Diseases, Peripheral Artery Diseases
  • By End User: Cardiology Centers, Ambulatory Surgery Centers (ASCs), Hospitals
Companies covered:

Boston Scientific Corporation, Medtronic, Abbott Laboratories, Biosensors International Group, Biotronik, Lepu Medical Technology, Terumo Medical Corporation, Cook Medical, Shandong JW Medical Systems, Stentys, AlviMedica Medical Technologies Inc., Amaranth Medical, Inc., HangZhou HuaAn Biotechnology Co., Ltd, XTENT, Inc., Cardionovum GmbH, Cordis Corporation, and Kyoto Medical Planning Co., Ltd.

Growth Drivers:
  • Increasing prevalence of cardiovascular diseases
  • Increasing drug eluting stents product launch and approvals
Restraints & Challenges:
  • Product Recall

Figure 2. Global Drug Eluting Stents Market Share (%), by Region, 2022

Drug Eluting Stents  | Coherent Market Insights

Global Drug Eluting Stents Market – Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe, and the World Health Organization declared it a public health emergency on January 30, 2020.

COVID-19 has affected the economy in three main ways: by directly affecting the production and demand for drugs and vaccines, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries such as China, India, Saudi Arabia, the UAE, Egypt, and others faced problems with regard to the transportation of drugs and vaccines from one place to another.

The COVID-19 pandemic also had a significant impact on the global drug eluting stents market, owing to increasing demand of drug eluting stents. For instance, in January 2022, a paper was published by National Center for Biotechnology Information, among the patients of COVID-19 stent thrombosis during the coronavirus pandemic around 35.3% patients underwent placement of new drug-eluting stent.

Global Drug Eluting Stents Market: Key Developments

In February 2020, BIOTRONIK, a medical device company, obtained CE Mark certification for Orsiro mission, a drug eluting stent. The stent shows next-level deliverability for acute performance. The stent is used for improving coronary luminal diameter in patients with coronary artery disease. Safety, efficacy, and clinical performance of Orsiro stent have been investigated in clinical studies with more than 48,500 patients enrolled.

Global Drug Eluting Stents Market: Restraint

Major factors restraining the global drug eluting stents market growth include product recall. For instance, in June 2020, the U.S. FDA sent a recall letter to Abbott, a medical device company, for its product Xience Sierra TM Everolimus Eluting Coronary Stent System, due to incorrect or no expiration date in the compliance chart of the product. Moreover, in April 2021, Boston Scientific, a manufacturing company, initiated a voluntary recall of its VICI VENOUS STENT System and VICI RDS VENOUS STENT System for Potential Stent Migration, product was recalled due to the migration or movement of stent from initial place of implantation and require another surgery to retrieve it, which may have high risk to the patients.

Key Players

Key players operating in the global drug eluting stents market include Boston Scientific Corporation, Medtronic, Abbott Laboratories, Biosensors International Group, Biotronik, Lepu Medical Technology, Terumo Medical Corporation, Cook Medical, Shandong JW Medical Systems, Stentys, AlviMedica Medical Technologies Inc., Amaranth Medical, Inc., HangZhou HuaAn Biotechnology Co., Ltd, XTENT, Inc., Cardionovum GmbH, Cordis Corporation, and Kyoto Medical Planning Co., Ltd.

Stents are usually used in the treatment of coronary angioplasty or percutaneous coronary intervention producers. The types of drug eluting stents include bare metal coronary artery stents, coronary artery restenosis, coronary artery stents, coronary revascularization, and others. Coronary artery stents are small cylindrical device that helps in improving blood flow through arteries to the heart by reducing blockages in the artery. Coronary artery stents are more beneficial for patients suffering from coronary artery diseases such as myocardial infarction.

Market Dynamics

Different Manufacturers like Boston Scientific., Medtronic, and others are focused on developing and launching new products and receiving product approvals from the United States Food and Drug Administration (U.S.FDA). For instance, in April 2019, Shanghai-based medical company MicroPort Medical (Group) Co., Ltd. received the U.S.FDA approval and CE (Conformité Européenne) Mark for ‘Firehawk Liberty’, a new generation rapamycin target eluting coronary stent system.

Furthermore, in May 2022, key players such as Medtronic, a global medical technology company, obtained the U.S. Food and Drug Administration (FDA) approval for Onyx Frontier drug-elution stent (DES), used to treat blockage of the heart arteries. It has enhanced delivering system and increased acute performance which is used to treat patients suffering from coronary artery disease. Onyx Frontier provides 4.50-5.00 mm sizes that can be expanded to 6.00 mm. It is specifically, designed to support extra-large vessels, while it shares the clinical indications as Resolute Onyx, including the most recent approval for patients that are at high risk of bleeding and may benefit from a dual anti-platelet therapy (DAPT) duration.

Moreover, an increase in the awareness of cardiovascular diseases such as heart failure and coronary heart disease cases globally is expected to fuel the global drug eluting stents market growth over the forecast period. For instance, in January 2020, according to the data published by the American Heart Association (AHA), the awareness of coronary artery disease is higher in females (54.4%) than males (45.6%). The mortality rate is also higher in females than in males with myocardial infarction (a dangerous condition caused by a lack of blood flow to the heart muscle).

Key features of the study:

  • This report provides an in-depth analysis of the global drug eluting stents market, market size (US$ Mn), and the compound annual growth rate (CAGR) (%) for the forecast period (2022-2030), considering 2021 as a base year
  • It elucidates potential revenue opportunity across different segments and explains an attractive investment proposition matrix for this market. It provides valuable insights about market drivers, restraints, opportunities, new product launches or approval, pipeline products, regional outlook, and competitive strategy adopted by the leading players.
  • It profiles leading players in the global drug eluting stents market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, key developments, and strategies
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions with respect to their future product launches, market expansion, and marketing tactics
  • Key companies covered as a part of this study include Boston Scientific Corporation, Medtronic, Abbott Laboratories, Biosensors International Group, Biotronik, Lepu Medical Technology, Terumo Medical Corporation, Cook Medical, Shandong JW Medical Systems, Stentys, AlviMedica Medical Technologies Inc., Amaranth Medical, Inc., HangZhou HuaAn Biotechnology Co., Ltd, XTENT, Inc., Cardionovum GmbH, Cordis Corporation, and Kyoto Medical Planning Co., Ltd.
  • The global drug eluting stents market report caters to various stakeholders in this industry, including investors, product developers, distributors, healthcare companies, research institutes, medical device companies, new entrants, and financial analysts
  • The global drug eluting stents market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would greatly benefit in decision-making through the various strategy matrices used in analyzing the global drug eluting stents market

Detailed Segmentation:

  • Global Drug Eluting Stents Market, By Drug
    • Sirolimus
    • Paclitaxel
    • Zotarolimus
    • Everolimus
    • Biolimus
    • Others
  • Global Drug Eluting Stents Market, By Coating Type
    • Polymer-based Coatings
    • Polymer-free Coatings
  • Global Drug Eluting Stents Market, By Application:
    • Coronary Artery Diseases
    • Peripheral Artery Diseases
  • Global Drug Eluting Stents Market, By End User:
    • Cardiology Centers
    • Ambulatory Surgery Centers (ASCs)
    • Hospitals
  • Global Drug Eluting Stents Market, By Region
    • North America
      • By Country:
        • U.S.
        • Canada
    • Europe
      • By Country:
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Country:
        • China
        • India
        • Japan
        • ASEAN
        • Australia
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Middle East
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Country/Region:
        • Central Africa
        • South Africa
        • North Africa
  • Company Profiles
    • Boston Scientific Corporation
      • Company Overview
      • Product Portfolio
      • Market Presence
      • Financial Overview
      • Key Developments
      • Strategies
    • Medtronic, Plc.
    • Abbott Laboratories
    • Biosensors International Group
    • Biotronik
    • Lepu Medical Technology
    • Terumo Medical Corporation
    • Cook Medical
    • Shandong JW Medical Systems
    • Stentys
    • AlviMedica Medical Technologies Inc.
    • Amaranth Medical, Inc.
    • HangZhou HuaAn Biotechnology Co.,Ltd
    • XTENT, Inc.
    • Cardionovum GmbH
    • Cordis Corporation
    • Kyoto Medical Planning Co., Ltd.

 “*” marked represents similar segmentation in other categories in the respective section.

Frequently Asked Questions

The global drug eluting stents market size is estimated to be valued at US$  2,897.2  million in 2022 and is expected to exhibit a CAGR of 6.6% between 2022 and 2030.
The increasing prevalence of several cardiovascular disease conditions such as heart attack, abnormal heart rhythms, heart failure, heart valve disease, and congenital heart disease, and increasing product launch are the major factors, which will propel the growth over the forecast period.
Coronary artery disease is the leading application segment in the market. 
Product recall is one of the major factors that is expected to hamper the market growth over the forecast period.
Major players operating in the market include Boston Scientific Corporation, Medtronic, Abbott Laboratories, Biosensors International Group, Biotronik, Lepu Medical Technology, Terumo Medical Corporation, Cook Medical, Shandong JW Medical Systems, Stentys, AlviMedica Medical Technologies Inc., Amaranth Medical, Inc., HangZhou HuaAn Biotechnology Co., Ltd, XTENT, Inc., Cardionovum GmbH, Cordis Corporation, and Kyoto Medical Planning Co., Ltd.

Related Reports

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo